Novoste
This article was originally published in The Gray Sheet
Executive Summary
Gains CE mark to begin European marketing the firm's Beta-Cath intracoronary radiation therapy device for the treatment of restenosis. The firm, which will handle European distribution directly, plans to ramp up its manufacturing capability, build product inventory and place staff in Europe over the next few months